GlassScriptPhysician profile
Luis Celestino Afonso
NPI 1023058575
$5,369.84
in general payments reported to CMS, 2019-2025
31 companies · $1,584 in 2025
The $1,584 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $562 · 2020: $448 · 2021: $762 · 2022: $566 · 2023: $627 · 2024: $822 · 2025: $1,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,032.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $948.75 | 2021-2025 | Micra, Linq II, Cobalt Dr Mri Surescan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $615.58 | 2019-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $432.08 | 2020-2025 | Amvuttra |
| Pfizer INC. | $414.65 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $345.77 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $326.82 | 2021-2025 | Verquvo, Capvaxive |
| Amgen INC. | $250.43 | 2019-2025 | Repatha, Repatha |
| Lantheus Medical Imaging, INC. | $208.10 | 2020-2024 | |
| Boston Scientific Corporation | $195.48 | 2023-2025 | Emblem Mri S-Icd, Empower Leadless Pacemaker System_crm, Lux-Dx Insertable Cardiac Monitor |
| Novo Nordisk INC | $192.36 | 2024-2025 | Wegovy |
| Kestra Medical Technology Services, INC. | $189.42 | 2024-2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $165.60 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $162.96 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $162.94 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.47 | 2021-2025 | Jardiance |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $152.23 | 2019 | |
| Abbott Laboratories | $66.80 | 2025 | Aveir |
| Kiniksa Pharmaceuticals, LTD. | $57.65 | 2021-2022 | |
| Medtronic Vascular, INC. | $47.59 | 2020 | |
| Sobi, INC | $36.76 | 2021 | |
| Cleerly, INC. | $34.10 | 2025 | Cleerly Labs, Cleerly Ischemia |
| United Therapeutics Corporation | $33.73 | 2025 | Tyvaso |
| Actelion Pharmaceuticals US, INC. | $25.25 | 2025 | Opsumit, Uptravi |
| Bridgebio Pharma, INC. | $24.64 | 2025 | Attruby |
| Bracco Diagnostics INC. | $22.76 | 2019 | |
| Esperion Therapeutics, INC. | $22.59 | 2020 | |
| Edwards Lifesciences Corporation | $20.70 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $18.87 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $13.83 | 2022 | |
| Alexion Pharmaceuticals, INC. | $12.81 | 2022 | |
| Corcept Therapeutics | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Afonso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.